- Home
- PTGX
as of 01-28-2026 3:51pm EST
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | NEWARK |
| Market Cap: | 5.1B | IPO Year: | 2016 |
| Target Price: | $93.00 | AVG Volume (30 days): | 788.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.72 | EPS Growth: | -73.17 |
| 52 Week Low/High: | $33.70 - $96.54 | Next Earning Date: | 02-20-2026 |
| Revenue: | $209,217,000 | Revenue Growth: | -35.39% |
| Revenue Growth (this year): | -88.06% | Revenue Growth (next year): | 409.41% |
AI-Powered PTGX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Protagonist Therapeutics Inc. (PTGX)
President and CEO
Avg Cost/Share
$83.19
Shares
4,068
Total Value
$338,416.92
Owned After
574,505
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$82.00
Shares
5,000
Total Value
$410,000.00
Owned After
84,115
SEC Form 4
President and CEO
Avg Cost/Share
$84.03
Shares
24,890
Total Value
$2,091,470.25
Owned After
574,505
Chief Medical Officer
Avg Cost/Share
$82.28
Shares
5,000
Total Value
$411,400.00
Owned After
84,115
SEC Form 4
President and CEO
Avg Cost/Share
$84.59
Shares
19,315
Total Value
$1,633,855.85
Owned After
574,505
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$82.42
Shares
13,151
Total Value
$1,083,905.42
Owned After
84,115
SEC Form 4
President and CEO
Avg Cost/Share
$82.48
Shares
34,438
Total Value
$2,840,446.24
Owned After
574,505
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$82.48
Shares
9,514
Total Value
$784,714.72
Owned After
84,115
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Ali Asif | PTGX | Chief Financial Officer | Jan 27, 2026 | Sell | $83.13 | 46,203 | $3,841,037.42 | 78,523 | |
| PATEL DINESH V PH D | PTGX | President and CEO | Jan 27, 2026 | Sell | $83.19 | 4,068 | $338,416.92 | 574,505 | |
| MOLINA ARTURO MD | PTGX | Chief Medical Officer | Jan 27, 2026 | Sell | $82.00 | 5,000 | $410,000.00 | 84,115 | |
| PATEL DINESH V PH D | PTGX | President and CEO | Jan 26, 2026 | Sell | $84.03 | 24,890 | $2,091,470.25 | 574,505 | |
| MOLINA ARTURO MD | PTGX | Chief Medical Officer | Jan 26, 2026 | Sell | $82.28 | 5,000 | $411,400.00 | 84,115 | |
| PATEL DINESH V PH D | PTGX | President and CEO | Jan 23, 2026 | Sell | $84.59 | 19,315 | $1,633,855.85 | 574,505 | |
| MOLINA ARTURO MD | PTGX | Chief Medical Officer | Jan 23, 2026 | Sell | $82.42 | 13,151 | $1,083,905.42 | 84,115 | |
| Ali Asif | PTGX | Chief Financial Officer | Jan 20, 2026 | Sell | $82.48 | 8,588 | $708,338.24 | 78,523 | |
| PATEL DINESH V PH D | PTGX | President and CEO | Jan 20, 2026 | Sell | $82.48 | 34,438 | $2,840,446.24 | 574,505 | |
| MOLINA ARTURO MD | PTGX | Chief Medical Officer | Jan 20, 2026 | Sell | $82.48 | 9,514 | $784,714.72 | 84,115 |
Compare PTGX vs Leading Stocks
See how PTGX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PTGX Protagonist Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.